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ABSTRACT
Introduction: In clinical trials, liraglutide has
proven to be an effective drug for the treatment
of type 2 diabetes mellitus (T2DM). The
real-world effectiveness of liraglutide has been
investigated in numerous studies. The aim of
this systematic literature review is to collate
evidence on the real-world clinical effectiveness
of liraglutide.
Methods: A review of publications from
Medline, EMBASE, the Cochrane Library, and
conference proceedings was conducted to
identify observational studies that assessed the
clinical effectiveness of liraglutide in real-world
clinical practice. This review was conducted
according to the National Institute of Health
and Care Excellence (NICE) guidance. No
language or time limits were applied, except to
the conference proceedings (2013–2015).
Endpoints for data extraction were decided a
priori. Study quality appraisal was done for
full-text journal articles.
Results: Of 124 publications included in the
review, 43 were full-text articles. Liraglutide
significantly reduces glycated hemoglobin
(HbA1c) within 6 months of initiating
treatment (mean change in HbA1c from
baseline: -0.9% to -2.2%; HbA1c \7.0%:
29.5–65.0%). The NICE composite endpoint
(HbA1c reduction C1% and weight
reduction C3%) was met in 16.9–47.0% of
patients with liraglutide treatment. Liraglutide
therapy led to a mean change in absolute
weight from baseline of -1.3 to -8.65 kg.
Liraglutide treatment was well tolerated in
patients with T2DM. The rate of occurrence of
hypoglycemia with liraglutide monotherapy
was B0.8%. Hypoglycemia was more common
in patients taking antidiabetic medications
(0.0–15.2%) together with liraglutide. The
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beneficial glycemic and weight effect of
liraglutide therapy in patients with T2DM was
maintained for at least 12 months.
Conclusion: Evidence from observational
studies reflecting real-world clinical practice
demonstrates that liraglutide therapy improves
glycemic control with a low risk of
hypoglycemia, and is associated with
significant weight loss in patients with T2DM.
These observations are consistent with clinical
trial findings.
Funding: Novo Nordisk A/S, Søborg, Denmark.
Keywords: Effectiveness; HbA1c;
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INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a chronic
metabolic disorder characterized by increased
blood glucose levels, i.e., hyperglycemia, which
over time can cause microvascular and
macrovascular complications [1]. The main
goal of T2DM treatment is to achieve and
maintain patients’ individual target blood
glucose levels, thus reducing the occurrence of
complications [2].
There are several guidelines for the
management of T2DM including those
developed by the International Diabetes
Federation (IDF) [3], the American Diabetes
Association (ADA) [4], the American
Association of Clinical Endocrinologists
(AACE)/American College of Endocrinology
(ACE) [5], and the National Institute of Health
and Care Excellence (NICE) from the UK [6].
The treatment recommendations are generally
consistent but with some differences. For
example, the ADA and the European
Association for the Study of Diabetes (EASD)
suggest a treatment algorithm for patients with
T2DM [7] which suggests that patients with
T2DM should initially be offered education in
lifestyle changes, with advice to lose weight by
changing dietary habits and increasing physical
activity. If a patient’s blood glucose level is not
decreased to, and maintained at, the
individualized target glycated hemoglobin
(HbA1c) levels [7], it is recommended that
medical treatment with anti-diabetic drugs be
initiated. Over the years, glucagon-like peptide
(GLP-1) receptor agonists (RAs) have become
integral as second- or third-line therapies in
many treatment guidelines, such as the ADA/
EASD, the AACE, and the IDF [3–7].
GLP-1 RAs are one among many treatment
options available for patients with T2DM.
GLP-1 RAs mimic the effects of endogenous
GLP-1, which regulates plasma glucose levels by
stimulating the secretion and biosynthesis of
insulin and by inhibiting the secretion of
glucagon and by delaying the gastric emptying
of food and reducing food intake [8, 9]. Based
on this mechanism of action, GLP-1 RA has
effects on controlling glucose level and
reducing body weight. Liraglutide was the
second GLP-1 RA that was approved for the
treatment of T2DM by the European Medicines
Agency (EMA) and the US Food and Drug
Administration (FDA) in 2009 and 2010,
respectively. Currently, liraglutide is the most
used GLP-1 RA worldwide [10]. The efficacy and
safety of liraglutide mono- and combination
therapy have been evaluated in the Liraglutide
Effect and Action in Diabetes (LEAD) clinical
program which consisted of six clinical trials
[11–16], and recently a clinical trial comparing
liraglutide head-to-head with lixisenatide was
finalized [17]. There exist a number of different
clinical trials on the efficacy of liraglutide,
among others comparative trials vs. albiglutide
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[18], dulaglutide [19], exenatide [20], sitagliptin
[21, 22], switching to GLP-1 RA from sitagliptin
[23] and with other oral antidiabetic drugs
(OADs; dipeptidyl peptidase-4 inhibitors
[DPP-4i], sulfonylurea [SU], glinide, metformin
[MET], a-glucosidase inhibitor, or
thiazolidinedione [TZD]) [24]. Furthermore,
one Japanese trial assessed liraglutide in
combination with insulin [25]. Results from all
these trials consistently showed that patients
treated with liraglutide had significantly
improved glycemic control (with a high
proportion of patients reaching HBA1c\7.0%
at the end of the trial) and achieved substantial
reductions in absolute body weight.
Importantly, these beneficial effects of
liraglutide occurred with a low risk of
hypoglycemia, and the drug was well tolerated
in patients with T2DM [11–25].
Established as a drug with robust clinical
efficacy and safety profile in controlled settings,
the clinical effectiveness and safety of liraglutide
for the treatment of patients with T2DM have
also been investigated in observational studies
reflecting real-life clinical practice. We performed
a systematic literature review to evaluate the
effectiveness of liraglutide for the treatment of
patients with T2DM in real-world clinical
practice. The goal of the review is to provide a
succinct overview of the evidence on the clinical
effectiveness of liraglutide which could help
guide clinical decision making and assist
clinicians in deciding how different therapies fit
into the current treatment algorithm, and help
inform current and future treatment guidelines
for the management of patients with T2DM.
METHODS
This systematic literature review was conducted
in accordance with the NICE guidance to obtain
relevant information using a consistent,
reproducible, and transparent methodology
[26]. According to this guidance, this process
involves the development of a study protocol
(see supplementary file 1), parallel review of
retrieved publications by two independent
researchers for the selection of relevant
publications, followed by a full-evidence data
extraction and quality assessment of study
methodology, results, and implication of
results to routine T2DM clinical practice.
Search Strategy
To collect evidence on the effectiveness of
liraglutide, different databases were selected.
These included Medline (1979–2016) and
EMBASE (1974–2016; searched simultaneously
via ProQuest), Cochrane (1992–2016; Cochrane
Database of Systematic Reviews [CDSR];
Database of Abstracts of Reviews of Effects
[DARE]; Cochrane Methodology Register
[CMR]; Health Technology Assessments
Database [HTA]; and The National Health
Services [NHS] Economic Evaluation Database
[EED]), health technology assessment websites,
and conference proceedings (International
Society for Pharmacoeconomics and Outcomes
Research [ISPOR], ADA, EASD, World Diabetes
Congress-IDF [WDC-IDF]).
The search terms included both free-text and
Emtree/MeSH terms of indication, clinical
effectiveness, comparative effectiveness,
generic and brand name of liraglutide, and
were designed to meet the requirements
outlined in NICE guidelines for the methods
of technology appraisal [26]. Complex search
strings, combining extensive lists of search
terms for indication and topic, were used to
search the databases through ProQuest. For
other databases, less complex search strings
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were used as the search engines provided fewer
options. In all databases, no language or time
limits were applied to ensure that no relevant
publications were missed. The annual meeting
abstracts were only searched for the last 3 years
(up until 2015), because it was assumed that
after 3 years these would have been published as
full publications in a peer-reviewed journal. The
search terms that were applied per database are
provided in the study protocol (see
supplementary file 1).
The database searches were executed on
October 13, 2015 and an updated search in
ProQuest was conducted on January 7, 2016.
Eligibility Criteria
After all the searches were performed, the
results were screened (based on title and
abstract followed by full-text review) in
parallel by two independent researchers after
the removal of duplicate publications. If the
researchers could not reach agreement on the
selection of a relevant publication, a third
independent researcher was consulted to
decide eligibility of the publication for the
review. The inclusion and exclusion criteria for
the screening and selection process are provided
in Table 1.
Data Extraction and Assessment of Study
Quality
The data extraction of selected studies was
performed by one researcher (AO). A second
researcher performed a thorough quality check
to assure all relevant data were extracted to the
correct parameter (WX). Endpoints for data
extraction were decided a priori. These
primarily included effectiveness (glucose
control and weight) and if the studies
identified in the literature search reported
safety endpoints (hypoglycemia, adverse
events [AEs], serious AEs) related to liraglutide
treatment for patients with T2DM, then these
were also included. No statistical analyses were
performed.
Following data extraction, a critical appraisal
of the quality of selected studies was performed
by a single researcher (AO), and reviewed by a
second researcher (WX). This quality
assessment was completed for all selected
observational studies that were published in
full text based on the recommendations of the
Centre for Reviews and Dissemination (CRD)
guidance for undertaking reviews in healthcare
[27]. The quality of full-text publications was
subjectively evaluated based on several criteria
including completeness of reporting, study
population and design, sample size, sampling
procedure, study follow-up duration, treatment
setting, patient inclusion and exclusion criteria
and patient enrollment and study completion
rates. In addition to this, quality appraisal was
further informed by assessing potential sources
of confounding and biases (e.g., patient baseline
characteristics, misclassification, selection bias,
reporting bias, etc.) which are known to be
prominent in observation studies. The
limitations described in the individual articles
from the authors’ perspective were also used to
guide the quality appraisal. The quality
assessment of abstracts was not performed as
study details were not adequately reported.
Data Reporting
The results section focuses mainly on the
findings from full-text journal publications
identified in the systematic literature review.
These findings are supplemented with
supportive evidence from the conference
abstracts. This approach for presentation was
chosen because full-text publications are peer
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reviewed and considered to be of higher quality
than abstracts from annual conference
proceedings as complete methodological details
and results are reported in full-text articles.
Compliance with Ethics Guidelines
This article is based on previously conducted
studies and does not involve any new studies of
Table 1 Study eligibility criteria
Item Inclusion criteria Exclusion criteria
Population Patients with T2DM Type 1 diabetes mellitus
Gestational diabetes
Other diseases
Intervention Treatment regimens including liraglutide Insulin therapy
NIADs
Comparator Treatment regimens including NIADs
TZD (e.g., pioglitazone)
DPP-4i (e.g., sitagliptin or saxagliptin)
SGLT2 inhibitor (e.g., dapagliﬂozin or
canagliﬂozin)






Outcomes Clinical effectiveness and safety of liraglutide
Comparative effectiveness and safety of
liraglutide compared to other NIADs
Studies not reporting the clinical effectiveness/safety of
either liraglutide compared to other NIADs











DPP-4i dipeptidyl peptidase-4 inhibitor, GLP glucagon-like peptide, MET metformin, NIAD non-insulin antidiabetic drug,
OAD oral antidiabetic drug, RA receptor agonist, RCT randomized controlled trials, SGLT2 sodium-glucose cotransporter
type-2, SU sulfonylurea, T2DM type 2 diabetes mellitus, TZD thiazolidinedione
Diabetes Ther (2016) 7:411–438 415




The database searches resulted in 220
publications from Medline and EMBASE (via
ProQuest). No publications were identified in
the Cochrane library. A total of 303
publications were found from conference
proceedings. After removing 88 duplicates
from a total of 523 publications, the title and
abstracts of 435 publications were screened for
eligibility to a full-text screening. Of 435
publications, 284 were excluded based on title
and abstract screening. Of 151 publications, 81
were abstracts from conference proceedings
and, therefore, only 70 full-text publications
were reviewed for eligibility by full-text
screening based on the pre-defined study
eligibility criteria. Of these 70 full-text
publications, 27 were excluded: 5, 17, and 5
records due to population, outcome, and study
design irrelevance, respectively. Thus, 43
full-text publications were included.
One-hundred and twenty-four publications
were eventually included in this literature
review. Of these, 43 were full-text journal
articles, and 81 were abstracts identified from
databases of conference proceedings or from
published supplements of conference
proceedings. The search and selection
procedure is shown in the PRISMA
flowchart (Fig. 1).
Study Characteristics
More than half of the 43 full-text journal
articles [28–70] had a study design which
involved analyses of data that were previously
collected from patient medical record/
chart review from hospitals, or databases
(53.5%; N = 23) [28, 30–33, 37, 39, 40, 43,
44, 46, 49–51, 54–58, 61, 62, 65, 70]. The
majority of the studies assessed the clinical
effectiveness of liraglutide without an active
comparator (81.4%; N = 35) [28, 29, 31,
34, 36–39, 41–49, 51–55, 57, 60–64, 66–71].
Real-world studies with comparators were less
frequently observed (18.6%; N = 8); the most
common comparators for liraglutide were:
sitagliptin or any DPP-4i (N = 6)
[32, 33, 35, 40, 56, 58], exenatide (N = 3)
[33, 35, 50], glimepiride or any other SUs
(N = 2) [30, 35], pioglitazone or other TZDs
(N = 1) [35], and MET (N = 1) [35]; note: these
numbers do not add up because some studies
had more than one comparator. The most
frequently observed follow-up duration from
these publications was C12 months (46.5%;
N = 20) [28–47], followed by 6–12 months
(34.9%; N = 15) [48–62], and\6 months
(18.6%; N = 8) [63–70]. Real-world studies
frequently reported data on the effect of
liraglutide from outpatient settings (30.2%;
N = 13) [34, 39, 40, 42–44, 49,
55, 58, 60, 61, 66, 67]. The geographical scope
of the review included studies from Europe
(N = 24), the USA (N = 5), and Asia–Pacific
(N = 14; see supplementary file 2).
Study characteristics from the abstracts
(N = 81; see supplementary file 3 for the full
list of conference abstracts included in this
review) were similar to those reported from
full-text publications. The majority of
conference abstracts reported findings from
studies involving analyses of already available
data (60.5%; N = 49), followed by those based
on prospective study designs (24.7%; N = 20).
For the remaining abstracts (14.8%; N = 12),
information on study design was not reported.
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Most of the studies assessed liraglutide without
an active comparator (75.3%; N = 61). The
common comparators were exenatide (N = 9),
sitagliptin or any DPP-4i (N = 8), and
glimepiride (N = 2). The most frequent
follow-up duration in the studies
was C12 months (N = 36), followed
by C6–12 months (N = 27), and\6 months
(N = 13). Five studies did not have
information on study duration. The treatment
effect of liraglutide from outpatient and
inpatient settings was reported in 16 and 2
studies, respectively. The remaining abstracts
did not specify the treatment setting.
Quality Appraisal of Full-Text Articles
Findings from the quality appraisal of 43
full-text journal publications are presented in
supplementary file 4. Generally, the study
Fig. 1 PRISMA ﬂow diagram. No studies were excluded
due to intervention/comparator at the full-text screening
stage. Other sources include publications from different
conference proceedings (see supplementary ﬁle 1). aPa-
tients were solid organ transplant recipients or had other
serious comorbidities. bResults were reported for overall
glucagon-like peptide-1 receptor agonist (no differentiation
for liraglutide and exenatide); or data were unavailable in
the full-text article. ti, ab title and abstract
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designs were appropriate to assess the clinical
effectiveness of liraglutide in routine clinical
practice. The review findings allow
understanding of the outcomes from
real-world clinical practice when liraglutide is
prescribed according to local guidelines.
Common limitations of some of the studies
that were identified included small sample size,
missing data, and limited generalizability to the
patient setting or study country. Some studies
did not adjust for potential confounding by
measured and unmeasured factors like
prescription bias. Confounding variables such
as the use of other medications, baseline
severity of disease and duration of diabetes,
values of comorbidity indices, baseline
prevalence of comorbidities, and body mass
index (BMI) were also not addressed between
intervention and comparator groups. Notably,
these study limitations are typically reported in
observational studies [72].
Patient Baseline Characteristics
In the full-text publications (N = 43), 7413
patients were treated with liraglutide. The
mean age of patients with T2DM on liraglutide
treatment was between 43.6 and 63.5 years at
baseline. The majority of publications (N = 22)
included more male patients (50.5–74.4%) than
female patients. In the remaining 21 studies,
male patients comprised 29.0–49.4% of the
total study population. Mean duration of
T2DM ranged from 5 to 15.8 years. The mean
baseline HbA1c level of patients with T2DM
before liraglutide treatment was between 7.2%
and 9.8%. Mean baseline weight and mean BMI
were 63.8–120 kg and 24.7–38.6 kg/m2,
respectively (see supplementary file 2).
The average dosage of liraglutide varied by
country (dosage information was not available
for 9 publications [32, 35, 46, 49–51,
56, 58, 70]). In all the studies from Japan,
patients were started at a dosage of 0.3 mg per
day and titrated up to 0.9 mg per day in
increments of 0.3 mg per week [38, 40, 54,
55, 61, 68, 70]. The recorded liraglutide dose
used in real-world studies was higher in the USA
than in Europe, as 1.8 mg was used more often
than 1.2 mg [28, 49, 56, 73]. In Europe, the use
of both 1.2 and 1.8 mg doses of liraglutide was
documented. Notably, most of the patients
from European studies received liraglutide
1.2 mg, and a subgroup of patients in these
studies had the dose escalated to 1.8 mg.
In studies comparing liraglutide with active
comparators, baseline patient characteristics
were generally balanced between treatment
groups. Some differences were observed in the
baseline characteristics, especially regarding use
of concomitant and previous antidiabetic
therapy. Concomitant SU, MET, and, to an
extent, basal/pre-mixed insulin use was similar
in patients treated with exenatide or liraglutide.
There was insufficient information on the use of
concomitant medications in patients using
DPP-4i or pioglitazone compared to liraglutide.
Information on the use of prior therapies varied
between the studies.
Patient characteristics from conference
abstracts largely showed a similar trend to
those observed for patient baseline
characteristics from full-text articles.
Clinical Effectiveness
Glucose Control
HbA1c: Change in HbA1c Level The clinical
effectiveness of antidiabetic drugs on blood
glucose control is measured by HbA1c (which
is widely used as a measure of average glucose
level over the preceding months before the time
of measurement) and/or plasma glucose level
(either fasting or post-prandial) [6, 74].
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The following measurements were reported
by the identified observational studies regarding
HbA1c level: change in mean HbA1c from
baseline to end-of-study, and proportion of
patients achieving widely accepted HbA1c
targets for patients with T2DM (i.e., \7% or
B6.5%).
One-hundred and six publications reported
the changes in HbA1c from baseline to
end-of-study, for patients with T2DM treated
with liraglutide. Of these, 38 were full-text
articles [28–34, 36–53, 55–60, 62, 64,
66, 67, 69, 70]. Study attributes and patient
baseline characteristics from the included
studies are provided in supplementary file 2.
Of the 38 full-text publications, 18 studies
reported an average follow-up duration of
C12 months [29–33, 36–40, 42–47], followed
by 15 studies with an average follow-up period
of C6–12 months [34, 48, 49, 52–60, 62, 73].
The remaining five studies had an average
follow-up period of B6 months [64, 66,
67, 69, 70].
The identified studies reported mean
baseline HbA1c in the range of 7.5–9.8% and
end-of-study HbA1c ranging from\6% to 8.5%
after liraglutide treatment
[29–34, 36–50, 52–60, 62, 64, 66, 67, 69, 70]. It
was reported that liraglutide therapy led to a
mean HbA1c change from baseline of -0.6% to
-2.26% (see Fig. 2). Mean changes in HbA1c
from baseline to end-of-study from studies
conducted in Europe (N = 21), the USA
(N = 4), and Asia–Pacific (N = 13) were -0.8%
to -1.9%, -0.8% to -0.99%, and -0.6% to
-2.26%, respectively (see Fig. 2). Real-world
studies demonstrate evidence of lowering
blood glucose levels regardless of baseline
HbA1c level and follow-up durations in
patients with T2DM treated with liraglutide
(Fig. 2) [28–34, 36–53, 55–60, 62, 64,
66, 67, 69, 70].
HbA1c: Proportion of Patients Achieving
HbA1c Target of <7% and £6.5% The
guidelines of the ADA (2015) [2] and Canadian
Diabetes Association (CDA) suggest multiple
goals of therapy, including attaining the
composite endpoint of HbA1c\7%, no
incidence of hypoglycemia, and/or no weight
gain (or weight loss if obese) in patients with
T2DM. More or less stringent targets may be
appropriate if these can be achieved without
significant hypoglycemia or AEs. The AACE
recommend a stringent glycemic target of
HbA1c B6.5% with low risk of hypoglycemia
[75], which is further endorsed by NICE [74]. A
total of 37 publications had data on the
proportion of patients achieving the HbA1c
targets of\7.0% and B6.5%.
Overall, 29.3–64.5% [28–32, 34, 36,
39, 42, 43, 45, 46, 48, 49, 52–54, 56–58,
70, 73] and 22.05–41.03% [28, 42, 45, 49,
52, 53, 56] patients with T2DM treated with
liraglutide met the\7% and B6.5% HbA1c
targets, respectively (for baseline characteristics
of study population in these studies; see
supplementary file 2).
Fasting and Post-Prandial Plasma
Glucose Thirty-six publications reported data
on the effect of liraglutide on fasting plasma
glucose (FPG) and post-prandial plasma glucose
(PPG). Of these, 20 were full-text articles.
Baseline FPG and PPG levels in patients with
T2DM treated in the real-world setting were
114.4–201 mg/dL and 167.57–252.5 mg/dL,
respectively. Overall, the evidence indicated
that liraglutide monotherapy and/or in
combination with oral glucose-lowering agents
was effective in reducing FPG and PPG levels.
FPG and PPG reductions from baseline to
end-of-study were in the range of 28.1–52.21
and 23.7–66.71 mg/dL, respectively.
End-of-study FPG and PPG observations
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ranged from 99.1–144 and 100.9–180.7 mg/dL,
which are close to the ADA-recommended
glycemic target for non-pregnant adults
(70–130 and\180 mg/dL, respectively) [76].
Body Weight
Reduction in body weight is associated with
improved glycemic control, insulin sensitivity,
and a reduced risk of developing cardiovascular
disease in obese patients with diabetes [77].
Seventy-four publications reported effect of
liraglutide on body weight in patients with
T2DM. Among these, 28 were full-text
publications [29–32, 34, 36, 37, 39, 40, 42, 43,
46, 48, 49, 51–55, 57–59, 62, 63, 65, 67, 69].
Only 4 studies had a follow-up period
of\6 months [63, 65, 67, 69]. The remaining
studies were equally divided between study
follow-up durations of C6–12 months (N = 12)
[34, 48, 49, 51–55, 57–59, 62] and C12 months
(N = 12) [29–32, 36, 37, 39, 40, 42, 43, 46, 62].
Overall, liraglutide treatment both as
monotherapy and in combination with oral
therapy led to significant weight loss in patients
with T2DM (Fig. 3). In patients with T2DM who
were prescribed liraglutide therapy baseline
weight and BMI range were 63.8–120 kg/m2
and 24.7–38.6 kg/m2, respectively.
Liraglutide therapy, over time, led to a mean
change in absolute weight from baseline of -1.3
to -8.65 kg. Mean changes in weight from
baseline in patients from Europe (N = 16), the
USA (N = 1), and Asia–Pacific (N = 11) were
-2.4 to -6.5 kg, -2.9 kg, and -1.3 to -8.7 kg,
respectively (Fig. 3). A few studies showed mean
weight reduction in patients with T2DM for up
to 2 years after initiating liraglutide treatment
[30, 40, 42, 43, 78].
Two studies that included 3210 patients
showed that patients experienced reduction in
body weight regardless of their baseline BMI
(25.0–40.0 kg/m2) after initiating liraglutide
therapy [42, 49]. Importantly, higher baseline
BMI was associated with larger absolute weight
loss in patients [42, 49]. Chitnis et al. [49]
(N = 3005 patients) reported larger weight
reductions with increasing BMI at the
6-month follow-up (BMI C 40 kg/m2: -4.0 kg;
BMI 35–39.9 kg/m2: –3.0 kg; BMI 30–34.9 kg/
m2: -1.9 kg; BMI 25–29.9 kg/m2: -1.5 kg;
P\0.01 for trend) [49]. Ponzani et al. [42]
(N = 205 patients) reported similar findings at
20 months (BMI C35 kg/m2: -6.66 kg;
BMI[30–35 kg/m2: -4.8 kg; BMI B30 kg/m2:
-2.98 kg) [42]. Both these studies had good
generalizability to real-world patients with
T2DM and obesity [42, 49]. These findings
reinforce that liraglutide could be beneficial,
not only in avoiding weight gain, but also in
helping patients with T2DM and obesity to lose
weight.
NICE Composite Endpoint: Percentage
of Patients with HbA1c Reduction ‡1%
and Weight Reduction ‡3%
Treatment guidelines for the management of
T2DM highlight the importance of not only
improving glycemic control but also of
managing obesity and hypertension [74].
Thus, composite endpoints are increasingly
reported in the assessment of novel diabetes
therapies. The NICE guidelines recommend that
GLP-1 mimetic therapy is continued if patients
with T2DM have a beneficial metabolic
response (a reduction of at least 11 mmol/mol
bFig. 2 Mean change in HbA1c from baseline in patients
with T2DM on liraglutide treatment in a Europe
(N = 21), b the USA (N = 4), and c Asia–Paciﬁc
(N = 13). a[11–25]. Note: data in the ﬁgures report
ﬁndings from full-text publications (38 of the 43 articles
that were included in the review). Data on HbA1c were
not reported in ﬁve full-text publications. Numbers in
parentheses on the x axis are references to the relevant
publications. HbA1c glycated hemoglobin, T2DM type 2
diabetes mellitus
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[1.0%] in HbA1c and a weight loss of at least 3%
of initial body weight in 6 months) [74].
Nine full-text articles reported data on
patients achieving the NICE composite
endpoint with liraglutide therapy (Table 2).
These studies reported that the NICE
composite endpoint was met in 20.1%
(baseline HbA1c: 9.7% [51]) to 47.0% (baseline
HbA1c: 8.2% [44]) of patients with T2DM who
were treated with liraglutide for at least
6 months.
Treatment with DPP-4i resulted in higher
proportions of patients meeting the NICE
composite endpoint (57–64%; baseline HbA1c:
8.1%) compared to liraglutide (28–32%;
baseline HbA1c: 9.6%) and exenatide (21–24%;
baseline HbA1c: 9.8%) [32, 33]. Notably, in
these studies baseline HbA1c level of patients
with T2DM was significantly different. In two
other studies, despite similar baseline
characteristics of patients, superior HbA1c and
weight reductions with liraglutide compared to
sitagliptin were reflected in routine clinical
practice (25% vs. 10%, respectively) [58, 79].
Data from conference abstracts mirrored these
findings.
Comparative Effectiveness
Data from studies comparing liraglutide with an
active comparator (sitagliptin or DPP-4i,
exenatide or GLP-1 RA, pioglitazone or TZD,
glimepiride or SU, and MET) were reported in
eight full-text articles (Table 3). Comparative
effectiveness data on the effect of liraglutide on
blood pressure, lipid profile, FPG, and PPG were
available from a small number of studies.
Change in HbA1c Level
An overview of the changes in the
post-interventional mean HbA1c level achieved
by liraglutide treatment compared to other
antidiabetic therapies is given in Table 3.
Overall, studies comparing liraglutide and
sitagliptin showed that liraglutide patients are
more likely to achieve HbA1c and weight
reductions compared with sitagliptin/DPP-4i
patients in routine clinical practice. Change in
mean HbA1c level with liraglutide treatment was
greater than that observed with sitagliptin or
DPP-4i treatment [32, 33, 40, 45, 56, 58]. A
retrospective database analysis in primary care
using the Clinical Practice Research Datalink in
the UK assessed the effectiveness of liraglutide
treatment in patients aged C18 years [58]. This
study showed superior HbA1c and weight
reductions with liraglutide compared to
sitagliptin. When controlling for potential
confounders, liraglutide was more likely than
sitagliptin to achieve an HbA1c reduction
of C1% [odds ratio (OR) = 2.29, 95%
confidence interval (CI): 1.62–3.25], the
composite target of HbA1c reduction C1% and
weight reduction C3% (OR = 2.99; 95% CI:
2.00–4.48), and a target HbA1c\7%
(OR = 2.11; 95% CI: 1.45–3.07) after 6 months
of treatment [58]. In another retrospective
chart audit conducted in the UK, greater
changes in HbA1c were seen with liraglutide
(–1.28%) in comparison with a pooled group of
DPP-4i (-0.74%; P\0.05) [32]. In the same
study, a subgroup analysis was conducted for
patients switching to liraglutide from DPP-4i
which resulted in a mean HbA1c reduction of
-0.9% for the liraglutide-treated patients
(P\0.05 vs. DPP-4i) [32]. Importantly, patients
bFig. 3 Mean reduction in weight from baseline in patients
with T2DM on liraglutide treatment in a Europe
(N = 16), b the USA (N = 1), and c Asia–Paciﬁc
(N = 11). a[11–25]. Note: data in the ﬁgure report
ﬁndings from 28 full-text publications (28 of the 43
articles that were included in the review). Data on weight
were not reported in 15 full-text publications. Numbers in
parentheses on the x axis are references to the relevant
publications. T2DM type 2 diabetes mellitus
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Table 2 Overview of studies reporting NICE Composite endpoint in real-world evidence studies










Liraglutide 8.8 (1.9) 287 6 25.10%
Sitagliptin 8.6 (1.5) 2781 10.4%a
Heymann et al.
2014 [51]
Liraglutide 9.7 (NA) 1101 6 20.10%
Russo et al.
2015 [44]
Liraglutide 8.2 (1.3) 115 12 47%
Evans et al.
2014 [33]
Liraglutide 9.6 (0.5) 229 12 32%
Exenatide 9.8 (0.8) 148 24%
DPP-4i 8.1 (0.4) 710 64%
Evans et al.
2013 [32]





















Liraglutide 8.7 (1.3) 453 6 20.10%
Karasik et al.
2013 [81]
Liraglutide 8.57 (1.20) 614 6 16.90%
Fatima et al.
2014 [82]
Liraglutide 8.7 (NA) 43 6 42%
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using GLP-1 RA (62.5%) had a higher baseline
BMI score and HbA1c values, and longer diabetes
duration than those on DPP-4i [32]. In other
studies, it was also observed that patients with
T2DM were switching their antidiabetic
treatment from DPP-4i to liraglutide [37, 51].
This likely reflects the superior effect of GLP-1 RA
therapy compared with DPP-4i, and emphasizes
the success of switching patients from a DPP-4i
to a GLP-1 RA [83, 84].
Four studies compared the glycemic effect of
liraglutide and exenatide. Overall, change in
HbA1c with liraglutide was slightly greater than
that observed with exenatide [32, 33, 45, 50]
(Table 3). Half of the studies reported statistically
significant reductions in HbA1c level with
liraglutide treatment compared to exenatide.
Notably, patients previously receiving
exenatide achieved a 0.8% HbA1c reduction
from baseline when switched to liraglutide, in
excess of the 0.32% reduction from baseline seen
in the clinical trial switching exenatide to
liraglutide. However, this may reflect
suboptimal previous exenatide therapy, as the
majority of these patients (62.6%) discontinued
exenatide due to tolerability issues [85].
Percentage of Patients Achieving HbA1c
Recommended Targets of <7% and
£6.5% Four studies reported comparative
data for percentage of patients achieving
recommended HbA1c targets [30, 50, 56, 58],
details of which are provided in Table 3.
Liraglutide showed better effectiveness in
achieving a higher percentage of patients
reaching the\7% HbA1c goal compared to
glimepiride at 18 months (51.3% vs. 11.6%;
P\0.001) [30] and compared to sitagliptin
(29.3% vs. 22.8%; OR = 2.11, 95% CI
1.45–3.07) [58]. Superior effectiveness of
liraglutide compared to sitagliptin was also
reported (52% vs. 44%; 6 months; OR = 1.55;
P\0.01) [56]. Using the HbA1c target of B6.5%,
liraglutide treatment also resulted in a higher
proportion of patients achieving the target
compared to sitagliptin (37 vs. 26%;
OR = 2.00; P\0.01) [56].
Glucose-lowering effectiveness was
comparable between liraglutide and exenatide
therapy. The percentage of patients
reaching\7% HbA1c target was reported as
64.5% and 54.4% after 6 months of therapy
with liraglutide and exenatide treatment,
respectively (P = 0.04) [50].
Body Weight Five studies provided
comparative data on the weight effect of
liraglutide treatment (Table 3)
[30, 32, 33, 40, 58]. Overall, these findings
demonstrated an added benefit of liraglutide
therapy in achieving HbA1c and weight
reductions compared with other diabetic
Table 2 continued









Liraglutide 7.69 (1.43) 180 6 27%
Sitagliptin 7.53 (1.50) 208 10%
BID twice daily, DPP-4i dipeptidyl peptidase-4 inhibitor, HbA1c glycated hemoglobin, N number of patients, NA not
available, NICE National Institute for Health and Care Excellence, SD standard deviation
a P\0.001
b Percentage of patients with HbA1c reduction C1% and weight reduction C3%
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therapies in real-world setting. Liraglutide
showed superior weight reduction compared
to sitagliptin [58], pioglitazone [40], and
glimepiride [30]. Furthermore, liraglutide was
effective in reducing patients’ weight among
those with previous therapy with insulin [62] or
a DPP-4i class drug [32].
Clinical effectiveness regarding body weight
reduction was comparable between liraglutide
and exenatide, though liraglutide usually led to




A total of 52 publications that were identified
in the literature search reported data on the
AE profile of liraglutide. Of these, 26 were
full-text articles. The rates of any AE ranged
from 0.0% to 64.3%. Gastrointestinal AEs
(nausea, vomiting, diarrhea, abdominal pain)
were the most commonly reported AE type
(0.51–42.9% of all reported AEs).
Gastrointestinal AEs were normally reported
in the first few weeks after initiating
liraglutide and when present, were
considered mild and transient. Skin
reactions/rash and headache were
uncommon (1–3%). Up to one-third of
patients withdrew from the studies because
of AEs (0–30%) [29, 36, 37, 39, 41, 44,
47, 48, 52, 54, 55, 57, 62, 64, 67]. The most
common reasons for withdrawal due to AEs
were reported to be vomiting and nausea.
From the identified full-text publications, to
our knowledge only four studies reported
occurrences of pancreatic disease
[29, 36, 37, 42] and one study reported
thyroid disease [36]. Two studies reported no
cases of pancreatic disease [29, 42]. Ghuman
et al. [37] reported 1 case of pancreatitis
among 152 patients that were followed for
up to 20 months. In the EVIDENCE study
(ClinicalTrials.gov identifier: NCT01226966),
3152 patients were followed up to 24 months
[36], in that period 8 medical AEs related to
pancreatic pathologies (pancreatitis [N = 1],
acute pancreatitis [N = 4], increased lipasemia
[N = 1], and hepato-pancreatic biological
disorder [N = 1]) and eight AEs linked to
thyroid pathologies (goiter [N = 2],
hyperthyroidism [N = 1], hypothyroidism
[N = 1], thyroid disorder [N = 1], thyroid
nodule [N = 1], thyroid cancer
[non-encapsulated papillary carcinoma;
N = 1], and thyroidectomy with no known
etiology [N = 1]) were reported. In this
observational study, one patient died of
pancreatic tumor 4 months after starting
treatment with liraglutide. Funch et al. [35]
assessed the relationship between liraglutide
and acute pancreatitis or pancreatic cancer in
a post-marketing safety assessment program
and reported no increased risk for acute
pancreatitis or pancreatic cancer in
association with liraglutide therapy.
Hyperglycemic events were not reported in
any of the publications covered by this review.
Hypoglycemia
Twenty-six publications reported data on
hypoglycemia (Table 4). Of these, 17 were
full-text articles. Data from full-text articles
showed that hypoglycemia-related events,
including minor hypoglycemia, occurred at low
rates (0.0–15.2%). Symptomatic hypoglycemia
occurred in 0.8% of patients with liraglutide
treatment and the occurrence of major (severe)
hypoglycemia was rare. In patients who received
liraglutide monotherapy, the rate of episodes of
hypoglycemia did not exceed 0.8%.
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Liraglutide (SU) 6 months 380 0.0%
Mori et al. 2011
[68]
Liraglutide (OADs) NA 8 % time in hypoglycemia (24-h) at pre-treatment: 0.1
(0.3)%
0.3 mg % time in hypoglycemia (24-h): 0.5 (1.7)%
0.6 mg % time in hypoglycemia (24-h): 0.1 (0.2)%
0.9 mg % time in hypoglycemia (24-h): 0.4 (1.3)%
Liraglutide only 12 % time in hypoglycemia (24-h): 0.0 (0.0)%
0.3 mg % time in hypoglycemia (24-h): 0.0 (0.1)%
0.6 mg % time in hypoglycemia (24-h): 0.0 (0.0)%
0.9 mg % time in hypoglycemia (24-h): 0.0 (0.0)%
Usui et al. 2013
[70]
Liraglutide (SU) 3 months 147 0.0%
Li et al. 2014
[56]
Liraglutide (OADs) 6 months 376 Severe: 0.5%
Sitagliptin (OADs) 1089 Severe: 0.61% (P = 0.81; between groups)
Mezquita-Raya
et al. 2015 [57]
Liraglutide (OADs) 6 months 740 All: 7.8%
Severe: 0.0%
Patients with insulin plus liraglutide: 10.6%
Patients with secretagogues plus liraglutide: 15.2%
(P = 0.369 vs. insulin plus liraglutide)
Patients with MET plus liraglutide: 1.6% (P\0.001





12 months 245 Minor: 0.07 to 0.55 events per patient per month
Major: 1 event at 3 months
Kesavadev et al.
2012 [53]





4 months 193 Minor: 5.7% (81.8% on concomitant SUs; 0.09%
patients on basal insulin)
Chitnis et al.
2014 [49]
Liraglutide only 6 months 3005 0.2–0.7%
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Hypoglycemia was more often reported in
studies with liraglutide combination therapy.
Nineteen studies reported hypoglycemia
episodes most frequently when liraglutide was
added to MET, SU, insulin, or other OADs
(0.0–15.2%).
Overall results from conference abstracts
echoed the conclusions from full-text
publications.
Data from comparative studies showed
similar rates of hypoglycemia in all
treatment groups, except for glimepiride
compared to liraglutide (18.4% vs. 2.9%;
P\0.001) [30]. Rates of hypoglycemia did
not vary at different follow-up durations. A
real-world study [36] that followed patients
with T2DM who were on liraglutide treatment
for 24 months reported a hypoglycemia rate
of 4.4% (N = 2009 patients) [36]. Notably, no
correlation between the occurrence of
hypoglycemia and liraglutide dosage (1.2 mg










Liraglutide only 12 months 31 0.0%
Evans et al. 2014
[33]
Liraglutide only 12 months 256 Symptomatic: 0.8%
Exenatide 148 Symptomatic: 0.9%
DDP-4i 710 Symptomatic: 0.8%
Vitagliano et al.
2014 [46]
BS 12 months 28 Symptomatic reactive: 28.5%
Liraglutide only 22 0.0%
Evans et al. 2013
[32]
DPP-4i 12 months 710 Symptomatic: 0.8%
Exenatide 148 Symptomatic: 0.9%
Liraglutide only 256 Symptomatic: 0.8%
Kaur et al. 2014
[67]
Liraglutide (OADs) 3 months 196 Minor: 3.0%
Lapolla et al.
2015 [39]





18 months 76 Major: 0.0%
Minor: 2.6%
Glimepiride 103 Major: 2.9%, P = 0.263 (between groups)
Minor: 18.4%, P\0.001 (between groups)
DPP-4i dipeptidyl peptidase-4 inhibitor, MET metformin, N number of patients, OAD oral antidiabetic drug, SU
sulfonylurea
OptumInsightTM and HealthCore are two major US healthcare companies’ administrative claims databases
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DISCUSSION
This systematic review reports evidence of the
effectiveness of liraglutide in T2DM treatment
in real-world clinical practice. The main
findings presented in this review were
obtained from full-text journal articles. The
results of the identified conference
proceedings in the last 3 years were consistent
with those of full text articles.
Overall, liraglutide was demonstrated to be an
effective (i.e., reduced HbA1c and body weight)
treatment for patients with T2DM. Clinical
effectiveness of liraglutide treatment was shown
in patients at T2DM with continued liraglutide
therapy (at least 12 months), and was well tolerated
in these patients in real-life clinical practice.
Glucose Control
Real-life use of liraglutide confirmed good
control of HbA1c level among patients with
T2DM (7413 patients treated with liraglutide),
measured by absolute change of HbA1c level,
the percentage of patients reaching HbA1c
treatment target (\7% or B6.5%), and the
NICE composite endpoint. In real-world
clinical practice, liraglutide treatment (alone
or in combination with other glucose-lowering
therapies) significantly reduces HbA1c (change
in mean HbA1c: -0.9% to -2.26%). This
change in HbA1c was clinically relevant and
corresponded well with that reported in the
randomized controlled trials (RCTs; -0.8% to
-1.83%) [11–25]. Among the included studies,
at least one-third of patients on liraglutide
therapy reached the HbA1c\7.0% target
(29.5–65.0%), which is comparable to the
proportion (35.0–45.0%) of patients reaching
the HbA1c target reported after 26 weeks of
liraglutide treatment in the LEAD RCTs [11–16].
The beneficial effect of liraglutide treatment on
FPG and PPG in patients with T2DM was also
demonstrated in the real-world setting.
The NICE composite endpoint was met in
16.90–47.0% of patients with T2DM who
initiated liraglutide therapy in real-life clinical
practice. The average decrease in HbA1c was
approximately 1% regardless of baseline HbA1c
level. We identified 3 studies, with a total of 268
patients treated with liraglutide, investigating
the effectiveness of liraglutide using different
doses of (0.3–1.8 mg) [43, 57, 68], which also
reflects the choice of doses in different countries.
Based on this limited number of patients, it
seems that HbA1c change from baseline to
post-intervention does not differ substantially
between different doses [43, 57]. However,
escalating liraglutide dose to 1.8 mg in patients
who do not respond to the 1.2 mg dose resulted
in an additional decrease in HbA1c
(-0.62% ± 0.17%; P\0.05 vs. liraglutide
1.2 mg) [43]. Dose escalation to 1.8 mg also
helped further body weight reduction [43].
Body Weight
Real-world studies showed substantial changes in
body weight (-1.3 to -8.65 kg). Studies showed
that patients experienced reduction in body
weight regardless of their baseline BMI
(25.0–40.0 kg/m2) after initiating liraglutide
therapy [42, 49]. In addition to this, higher
BMI at baseline was associated with slightly
greater weight loss with liraglutide treatment
[42, 49]. The effect of such weight loss in patients
with T2DM remains to be demonstrated;
however, this finding reveals that liraglutide
may help in improving patient quality of life in
patients with T2DM with overweight or obesity
[42, 49]. Statistically significant and numerically
larger reductions in BMI were demonstrated.
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It is important to note that both glycemic
control and weight effect of liraglutide in
patients with T2DM were maintained with at
least 12 months of liraglutide treatment
[29, 38, 39, 42, 45, 49, 78].
Comparative Effectiveness
Our review identified a few studies which
showed a beneficial effect of liraglutide both
in terms of glycemic and weight control when
patients switched from DPP-4i [32, 37, 51].
Generally, liraglutide achieved better
reductions in HbA1c and weight control in
patients with T2DM compared with continuing
DPP-4i/sitagliptin [58, 79], exenatide [32, 33],
glimepiride, and pioglitazone.
Safety
The safety profile of liraglutide was assessed
based on the systematic literature search that
included effectiveness outcomes as primary
endpoints. Overall, the safety profile of
liraglutide assessed in this review of real-world
studies was observed to be in line with what is
reported in the summary of product
characteristics (SmPC) for liraglutide [87]. The
occurrence of acute pancreatitis reported in the
EVIDENCE study (0.1%) is in agreement with
the SmPC for liraglutide (\0.2%) [87]. The
findings in this review confirm that liraglutide
could be safely used in real-world clinical
practice also in combination with other OADs.
The safety data corroborate findings from
clinical trials of liraglutide [88, 89] (AEs ranged
from 0.0% to 64.3% in real-world observational
studies compared to 33.0–56.0% in the LEAD
RCTs) [11–16]. Safety findings were also in line
with other RCTs assessing liraglutide [17–25].
For a detailed assessment of the real-world
safety profile of liraglutide, a new systematic
literature search specifying safety specific
outcomes would be needed as this was not
within the scope of the present review.
Biases and Confounding Factors
in Observational Studies
Although this review found comparable
effectiveness and safety profile of liraglutide in
the real-world and RCT settings, it is important
to note the difference in patient groups in
observational studies and the LEAD trials with
regard to patient baseline characteristics such as
duration of T2DM, baseline Hba1c level, and
BMI. Compared to the disease duration of
patients enrolled in the LEAD trials
(5.2–9.0 years), the average duration of T2DM
in patients in real-world setting was longer
(5–15.8 years), suggesting that patients were in
a slightly later stage of T2DM. The LEAD
program showed that liraglutide works in the
continuum of T2DM, and may provide greater
benefit when used earlier in the course of
disease progression [11–16]. Additionally,
patients with T2DM in the real-world setting
had a higher baseline HbA1c (7.5–9.8%) and
BMI (24.7–38.6 kg/m2) compared to the LEAD
clinical trials (baseline HbA1c: 8.1–8.6%; and
baseline BMI: 29.8–33.5 kg/m2) [88], suggesting
more severe disease and overweight/obesity in
T2DM real-world setting. Thus, liraglutide is
likely to show better clinical effectiveness in
real-world studies than that reported in RCTs if
used in patient groups with similar disease
duration and baseline disease severity.
Merits and Limitations of This Review
This systematic literature review conducted
according to NICE guidelines is the first of its
kind to summarize evidence on the real-world
use of liraglutide. Merits of this systematic
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literature review include its a priori design—set
inclusion and exclusion criteria, parallel
screening review performed independently by
two reviewers, and stringent quality control and
assessment. All the parameters and clinical
endpoints (i.e., HbA1c thresholds) reported
were consistent with those used in clinical
trials. Most of the studies were of good quality
based on the quality assessment of the study
design and methodology. The reporting quality
of the full-text journal articles was consistent in
relation to endpoints and use of liraglutide.
There were a few drawbacks with the quality of
the included studies. The majority of studies
included in this review had a moderate sample
size and were based on existing data. Most of
the studies were also designed as
non-comparative studies and need to be
interpreted carefully as they might present
some limitations in terms of bias and
confounding. Despite these limitations, a
similar pattern showing benefits of liraglutide
on HbA1c and weight is seen in real-world
clinical practice, which overall supports the
findings from RCTs [11–16].
CONCLUSIONS
Overall, the systematic literature review of
real-world observational studies reaffirms the
findings from clinical trials that liraglutide
monotherapy or combination therapy with
other OADs translates into therapeutic benefits
for patients with T2DM in routine clinical
practice.
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